W J S C World Journal Stem Cells Submit Manuscript httpswwwf6publishingcom World J Stem Cells 2022 March 26 143 264266 DOI 104252wjscv14i3264 ISSN 19480210 online LETTER TO THE EDITOR Mesenchymal stemstromal cells adjuvant therapy COVID19 associated acute lung injury cytokine storm Importance cell identification Jeanne Adiwinata Pawitan Specialty type Cell tissue engineering Provenance peer review Invited article Externally peer reviewed Peerreview model Single blind Peerreview reports scientific quality classification Grade A Excellent A Grade B Very good B Grade C Good C Grade D Fair 0 Grade E Poor 0 PReviewer Cai J China Tan JK Malaysia Tazegul G Turkey Received September 11 2021 Peerreview started September 11 2021 First decision November 17 2021 Revised November 23 2021 Accepted March 6 2022 Article press March 6 2022 Published online March 26 2022 Jeanne Adiwinata Pawitan Department Histology Faculty Medicine Universitas Indonesia Jakarta 10430 DKI Jaya Indonesia Jeanne Adiwinata Pawitan Stem Cell Medical Technology Integrated Service Unit Dr Cipto Mangunkusumo General HospitalFaculty Medicine Universitas Indonesia Jakarta 10430 DKI Jaya Indonesia Jeanne Adiwinata Pawitan Stem Cell Tissue Engineering Research Center Indonesia Medical Education Research Institute IMERI Faculty Medicine Universitas Indonesia Jakarta 10430 DKI Jaya Indonesia Corresponding author Jeanne Adiwinata Pawitan MD PhD Professor Department Histology Faculty Medicine Universitas Indonesia Gedung Anatomi Jl Salemba 6 Jakarta 10430 DKI Jaya Indonesia jeanneadiwipgmailcom Abstract Theoretically mesenchymal stem cells MSCs promising adjuvant therapy alleviate coronavirus disease 2019 COVID19associated acute lung injury cytokine storm Several published studies MSCs alleviate COVID19associated acute lung injury cytokine storm reported promising results However evidence came case report case series clinical trials limited number participants Therefore studies needed robust proof MSC beneficial effects Key Words COVID19 Mesenchymal stem cells Pneumonia Cytokine storm Acute respiratory distress syndrome The Authors 2022 Published Baishideng Publishing Group Inc All rights reserved WJSC httpswwwwjgnetcom 264 March 26 2022 Volume 14 Issue 3 Pawitan JA MSC therapy COVID19 Core Tip Several published studies mesenchymal stem cells MSCs alleviate coronavirus disease 2019associated acute lung injury cytokine storm reported promising results However evidence came case report case series clinical trials limited number participants Therefore robust proof needed The studies ongoing clinical trials MSCs sources theoretically angiotensinconverting enzyme 2 negative subsets preferable Therefore future reporting clinical trial results complete identity MSCs needs defined Citation Pawitan JA Mesenchymal stemstromal cells adjuvant therapy COVID19associated acute lung injury cytokine storm Importance cell identification World J Stem Cells 2022 143 264266 URL httpswwwwjgnetcom19480210fullv14i3264htm DOI httpsdxdoiorg104252wjscv14i3264 TO THE EDITOR I read minireview Zhang et al1 elaborately discussed prospects mesenchymal stemstromal cells MSCs coronavirus disease 2019 COVID19associated acute lung injuryacute respiratory distress syndrome In beginning authors pointed recently reported MSC based therapies deal cytokine storm pulmonary damage The report Leng et al2 enrolled 7 MSC treated subjects 3 controls The report showed favorable prognosis terms clinical recovery serum cytokine profile The second report MSC based therapy COVID19 case report Liang et al3 reported favorable outcome Though reports showed favorable outcomes I highly support opinion Zhang et al1 systematic elaboration therapeutics underlying mechanism far satisfactory The report enrolled subjects showed treatment control group unequal terms age patients severity disease The second report case report 1 patient23 provides lowest level evidence There reports assessed authors A case series 12 patients Terry4 intravenous infusions bone marrowderived MSCs Ryoncil Mesoblast The results showed 75 patients previously refractory experimental therapies free ventilators 10 d overall survival 83 Further recent randomized clinical trial Indonesia enrolled 40 patients gave umbilical cord UCderived MSCs results showed survival rate treatment group 25 times higher control group However patients comorbidities assessed survival rate treatment group 45 times compared controls Moreover significant decrease interleukin6 recovered patients result line antiinflammatory property MSCs5 Interestingly 70 clinical trials stages ongoing trials MSCs sources1 It interesting note Zhang et al1 pointed superiority angiotensinconverting enzyme 2 ACE2 negative subsets UCderived MSCs Leng et al2 Other studies MSCs COVID19 use ACE2 negative subsets MSCs35 A study showed ACE2 expression significantly higher adipose tissue bone marrowderived MSCs compared UC placentaderived MSCs In addition culture conditions passage impact ACE2 expression levels At higher passages 35 passages UC placentaderived MSCs expressed higher levels ACE26 I highly support opinion Zhang et al1 highly bioactive subpopulations heterogeneous MSCs need identified1 Therefore future studies use MSCs need completely report source culture conditions passage identity properties MSCs FOOTNOTES Author contributions Pawitan JA designed research performed research analyzed data wrote letter revised letter Conflictofinterest statement Jeanne Adiwinata Pawitan conflict OpenAccess This article openaccess article selected inhouse editor fully peerreviewed external reviewers It distributed accordance Creative Commons Attribution NonCommercial CC BY NC 40 license permits distribute remix adapt build work noncommercially license derivative works different terms provided original work properly cited use non commercial See httpscreativecommonsorgLicensesbync40 WJSC httpswwwwjgnetcom 265 March 26 2022 Volume 14 Issue 3 Pawitan JA MSC therapy COVID19 CountryTerritory origin Indonesia ORCID number Jeanne Adiwinata Pawitan 0000000265515238 SEditor Fan JR LEditor Filipodia PEditor Fan JR REFERENCES 1 2 3 4 5 6 Zhang LS Yu Y Yu H Han ZC Therapeutic prospects mesenchymal stemstromal cells COVID19 associated pulmonary diseases From bench bedside World J Stem Cells 2021 13 10581071 PMID 34567425 DOI 104252wjscv13i81058 Leng Z Zhu R Hou W Feng Y Yang Y Han Q Shan G Meng F Du D Wang S Fan J Wang W Deng L Shi H Li H Hu Z Zhang F Gao J Liu H Li X Zhao Y Yin K He X Gao Z Wang Y Yang B Jin R Stambler I Lim LW Su H Moskalev A Cano A Chakrabarti S Min KJ EllisonHughes G Caruso C Jin K Zhao RC Transplantation ACE2 Mesenchymal Stem Cells Improves Outcome Patients COVID19 Pneumonia Aging Dis 2020 11 216228 PMID 32257537 DOI 1014336AD20200228 Liang B Chen J Li T Wu H Yang W Li Y Li J Yu C Nie F Ma Z Yang M Xiao M Nie P Gao Y Qian C Hu M Clinical remission critically ill COVID19 patient treated human umbilical cord mesenchymal stem cells A case report Medicine Baltimore 2020 99 e21429 PMID 32756149 DOI 101097MD0000000000021429 Terry M Mesoblasts stem cell therapy shows 83 survival ventilatordependent covid19 patients Biospace 2020 cited 10 July 2022 Available httpswwwbiospacecomarticlemesoblastltdsstemcelltherapyshows83 percentsurvivalincovid19 patientstextMelbourne2C20Australia20and20New20Yorkstem20cell20candidate20Ryoncil20reme stemcel Dilogo IH Aditianingsih D Sugiarto A Burhan E Damayanti T Sitompul PA Mariana N Antarianto RD Liem IK Kispa T Mujadid F Novialdi N Luviah E Kurniawati T Lubis AMT Rahmatika D Umbilical cord mesenchymal stromal cells critical COVID19 adjuvant therapy A randomized controlled trial Stem Cells Transl Med 2021 10 12791287 PMID 34102020 DOI 101002sctm210046 Desterke C Griscelli F Imeri J Marcoux P Lemonnier T Latsis T Turhan AG BennaceurGriscelli A Molecular investigation adequate sources mesenchymal stem cells cell therapy COVID19associated organ failure Stem Cells Transl Med 2021 10 568571 PMID 33237619 DOI 101002sctm200189 WJSC httpswwwwjgnetcom 266 March 26 2022 Volume 14 Issue 3 Published Baishideng Publishing Group Inc 7041 Koll Center Parkway Suite 160 Pleasanton CA 94566 USA Telephone 19253991568 Email bpgofficewjgnetcom Help Desk httpswwwf6publishingcomhelpdesk httpswwwwjgnetcom 2022 Baishideng Publishing Group Inc All rights reserved